Precision.AI: Discovery TechnologyWe use Precision AI for Drug Discovery Based on the Therapeutic Area |
DrugTX.AI: Development TechnologyPlatform for clinical development, manufacturing and commercialization |
|||||||
| Therapeutic Area | Discovery Precision AI Technology | Modality | Molecule Name & Investigational Indication | Discovery | IND | Phase1 | Phase 2 | Phase 3 |
| Oncology | CancerTX.AI | AB | MY101 Pancreatic Cancer |
Discovery Collaboration: CancerAppy. Clinical Development: Partnering Available.
|
||||
| AB | MY102 Non Small Cell Lung Cancer |
Discovery Collaboration: CancerAppy. Clinical Development: Partnering Available.
|
||||||
| Children’s Diseases | PulmonaryTX.AI | SM | MY201 Chronic obstructive pulmonary disease (Pediatric Lung Disease) |
Discovery Collaboration: Undisclosed Children’s Hospital. Clinical Development: Partnering Available.
|
||||
| CancerTX.AI | AB | MY202 Non-Small Cell Lung Cancer |
Discovery Collaboration: Partnering Available. Clinical Development: Partnering Available.
|
|||||
| Alzheimer’s disease | NeurologyTX.AI | AB | MY301 Alzheimer Disease |
Discovery Collaboration: Partnering Available. Clinical Development: Partnering Available.
|
||||
| Specialized Immunology | ImmunologyTX.AI | AB | MY401 Systemic lupus erythematosus (SLE) |
Discovery Collaboration: Partnering Available. Clinical Development: Partnering Available.
|
||||
Collaborations are welcome for the use of Precision.AI in:
DrugTX.AI platform for drug development efforts in:
